CN104920499B - 一种复方消毒剂及其制备方法和应用 - Google Patents
一种复方消毒剂及其制备方法和应用 Download PDFInfo
- Publication number
- CN104920499B CN104920499B CN201510247163.4A CN201510247163A CN104920499B CN 104920499 B CN104920499 B CN 104920499B CN 201510247163 A CN201510247163 A CN 201510247163A CN 104920499 B CN104920499 B CN 104920499B
- Authority
- CN
- China
- Prior art keywords
- compound
- disinfectant
- compound disinfectant
- chlorhexidine
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 96
- 239000000645 desinfectant Substances 0.000 title claims abstract description 76
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 47
- 238000004659 sterilization and disinfection Methods 0.000 claims abstract description 24
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229960003260 chlorhexidine Drugs 0.000 claims abstract description 17
- 240000000691 Houttuynia cordata Species 0.000 claims abstract description 15
- 244000247747 Coptis groenlandica Species 0.000 claims abstract description 14
- 235000002991 Coptis groenlandica Nutrition 0.000 claims abstract description 14
- 235000013717 Houttuynia Nutrition 0.000 claims abstract description 14
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 11
- 241000628997 Flos Species 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims description 38
- 239000011159 matrix material Substances 0.000 claims description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 241000205585 Aquilegia canadensis Species 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- 241000245665 Taraxacum Species 0.000 claims description 9
- 229960002152 chlorhexidine acetate Drugs 0.000 claims description 9
- 229960003333 chlorhexidine gluconate Drugs 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 claims description 9
- 241000227129 Aconitum Species 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 239000008213 purified water Substances 0.000 claims description 8
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 235000011187 glycerol Nutrition 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 6
- 239000012535 impurity Substances 0.000 claims description 5
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 claims description 4
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 claims description 4
- 238000002425 crystallisation Methods 0.000 claims description 4
- 230000008025 crystallization Effects 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 230000000144 pharmacologic effect Effects 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 3
- 150000001336 alkenes Chemical class 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 230000000249 desinfective effect Effects 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- -1 polyoxyethylene Polymers 0.000 claims description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 3
- 229910052573 porcelain Inorganic materials 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 230000001954 sterilising effect Effects 0.000 abstract description 10
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 6
- 208000030961 allergic reaction Diseases 0.000 abstract description 6
- 239000004480 active ingredient Substances 0.000 abstract description 5
- 230000009965 odorless effect Effects 0.000 abstract description 5
- 206010059866 Drug resistance Diseases 0.000 abstract description 4
- 238000001228 spectrum Methods 0.000 abstract description 4
- 230000009967 tasteless effect Effects 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 240000001949 Taraxacum officinale Species 0.000 abstract description 3
- 230000000843 anti-fungal effect Effects 0.000 abstract description 3
- 229940121375 antifungal agent Drugs 0.000 abstract description 3
- 241000173529 Aconitum napellus Species 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 description 19
- 230000000844 anti-bacterial effect Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- WITLAWYGGVAFLU-UHFFFAOYSA-N 3-(6-methoxy-1,3-benzodioxol-5-yl)-8,8-dimethylpyrano[2,3-f]chromen-4-one Chemical compound C1=CC(C)(C)OC2=CC=C(C(C(C3=CC=4OCOC=4C=C3OC)=CO3)=O)C3=C21 WITLAWYGGVAFLU-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- MXTLAHSTUOXGQF-UHFFFAOYSA-O Jatrorrhizine Chemical compound COC1=CC=C2C=C3C(C=C(C(=C4)O)OC)=C4CC[N+]3=CC2=C1OC MXTLAHSTUOXGQF-UHFFFAOYSA-O 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- XWMMEBCFHUKHEX-MRTCRTFGSA-N (+)-Taraxasterol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC[C@]1(C)[C@@H]2CC[C@H]2[C@@H]3[C@H](C)C(=C)CC[C@]3(C)CC[C@]21C XWMMEBCFHUKHEX-MRTCRTFGSA-N 0.000 description 4
- QMKPCZNFLUQTJZ-UHFFFAOYSA-N (4aR)-10c-Hydroxy-1t.2c.4ar.6at.6bc.9.9.12ac-octamethyl-(8atH.12btH.14acH.14btH)-docosahydro-picen Natural products CC1CCC2(C)CCC3(C)C(CCC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C QMKPCZNFLUQTJZ-UHFFFAOYSA-N 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 4
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 4
- PTOJXIKSKSASRB-UHFFFAOYSA-O candicine Chemical compound C[N+](C)(C)CCC1=CC=C(O)C=C1 PTOJXIKSKSASRB-UHFFFAOYSA-O 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 4
- 208000001848 dysentery Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 235000013372 meat Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- NGFFRJBGMSPDMS-UHFFFAOYSA-N psi-Taraxasterol Natural products CC12CCC(O)C(C)(C)C1CCC1(C)C2CCC2C3C(C)C(C)=CCC3(C)CCC21C NGFFRJBGMSPDMS-UHFFFAOYSA-N 0.000 description 4
- ZSBXGIUJOOQZMP-BHPKHCPMSA-N sophoridine Chemical compound C1CC[C@@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-BHPKHCPMSA-N 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- HUTYZQWCTWWXND-NCTFTGAASA-N taraxasterol Natural products C[C@H]1[C@H]2C3=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)C[C@H](O)[C@@]2(C)CCC1=C HUTYZQWCTWWXND-NCTFTGAASA-N 0.000 description 4
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 4
- 229940033663 thimerosal Drugs 0.000 description 4
- KYWIYKKSMDLRDC-UHFFFAOYSA-N undecan-2-one Chemical compound CCCCCCCCCC(C)=O KYWIYKKSMDLRDC-UHFFFAOYSA-N 0.000 description 4
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 3
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000004500 asepsis Methods 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- KSMVZQYAVGTKIV-UHFFFAOYSA-N decanal Chemical compound CCCCCCCCCC=O KSMVZQYAVGTKIV-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 3
- 229940032091 stigmasterol Drugs 0.000 description 3
- 235000016831 stigmasterol Nutrition 0.000 description 3
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 2
- GRWFGVWFFZKLTI-IUCAKERBSA-N (-)-α-pinene Chemical compound CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 2
- HEVGGTGPGPKZHF-UHFFFAOYSA-N 1-(1,2-dimethyl-3-methylidenecyclopentyl)-4-methylbenzene Chemical compound CC1C(=C)CCC1(C)C1=CC=C(C)C=C1 HEVGGTGPGPKZHF-UHFFFAOYSA-N 0.000 description 2
- HJMDOAWWVCOEDW-UHFFFAOYSA-N 4,9-bis(3-methylbut-2-enoxy)furo[3,2-g]chromen-7-one Chemical compound O1C(=O)C=CC2=C1C(OCC=C(C)C)=C1OC=CC1=C2OCC=C(C)C HJMDOAWWVCOEDW-UHFFFAOYSA-N 0.000 description 2
- XVPBINOPNYFXID-JARXUMMXSA-N 85u4c366qs Chemical compound C([C@@H]1CCC[N@+]2(CCC[C@H]3[C@@H]21)[O-])N1[C@@H]3CCCC1=O XVPBINOPNYFXID-JARXUMMXSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 2
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 2
- XDVZNDLANFJOQR-UHFFFAOYSA-N Coptisine Natural products O=Cc1c2OCOc2ccc1C=C3/NCCc4cc5OCOc5cc34 XDVZNDLANFJOQR-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 240000001624 Espostoa lanata Species 0.000 description 2
- 235000009161 Espostoa lanata Nutrition 0.000 description 2
- 206010018612 Gonorrhoea Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 2
- RBBVPNQTBKHOEQ-KKSFZXQISA-O Phellodendrine Chemical compound C1CC2=CC(OC)=C(O)C=C2[C@H]2[N@+]1(C)CC(C=C(C(=C1)O)OC)=C1C2 RBBVPNQTBKHOEQ-KKSFZXQISA-O 0.000 description 2
- 208000008350 Pruritus Vulvae Diseases 0.000 description 2
- 241000207929 Scutellaria Species 0.000 description 2
- 208000007074 Trichomonas Vaginitis Diseases 0.000 description 2
- 208000025206 Trichomonas vaginitis urogenital infection Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 2
- LCXREBMNASQAOC-UHFFFAOYSA-N Worenine Chemical compound C1=C2C(C)=C(C=3C(=CC=4OCOC=4C=3)CC3)[N+]3=CC2=CC2=C1OCO2 LCXREBMNASQAOC-UHFFFAOYSA-N 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- FSLPMRQHCOLESF-UHFFFAOYSA-N alpha-amyrenol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CCC3C21C FSLPMRQHCOLESF-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- JFSHUTJDVKUMTJ-QHPUVITPSA-N beta-amyrin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C JFSHUTJDVKUMTJ-QHPUVITPSA-N 0.000 description 2
- QQFMRPIKDLHLKB-UHFFFAOYSA-N beta-amyrin Natural products CC1C2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C)CCC1(C)C QQFMRPIKDLHLKB-UHFFFAOYSA-N 0.000 description 2
- PDNLMONKODEGSE-UHFFFAOYSA-N beta-amyrin acetate Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4=CCC23C)C1(C)C PDNLMONKODEGSE-UHFFFAOYSA-N 0.000 description 2
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 2
- CRPUJAZIXJMDBK-UHFFFAOYSA-N camphene Chemical compound C1CC2C(=C)C(C)(C)C1C2 CRPUJAZIXJMDBK-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- LUXPUVKJHVUJAV-UHFFFAOYSA-M coptisine, chloride Chemical compound [Cl-].C1=C2C=C(C3=C(C=C4OCOC4=C3)CC3)[N+]3=CC2=C2OCOC2=C1 LUXPUVKJHVUJAV-UHFFFAOYSA-M 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- XTLWNMXYCHABQH-UHFFFAOYSA-N germanicol Natural products CC1(C)CCC2(C)CCC3(C)C(CCC4(C)C5(C)CCC(O)C(C)(C)C5CCC34C)C2=C1 XTLWNMXYCHABQH-UHFFFAOYSA-N 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229930014456 matrine Natural products 0.000 description 2
- 229930015582 oxymatrine Natural products 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- GGGUGZHBAOMSFJ-GADYQYKKSA-N taraxerol Chemical compound CC([C@@H]1CC2)(C)[C@@H](O)CC[C@]1(C)[C@@H]1[C@]2(C)C2=CC[C@@]3(C)CCC(C)(C)C[C@H]3[C@]2(C)CC1 GGGUGZHBAOMSFJ-GADYQYKKSA-N 0.000 description 2
- HYTFUKZLSYXRDX-UHFFFAOYSA-N taraxerol Natural products CC1CCCC2C3(C)CCC4(C)C5CC(C)(C)CCC5(C)C=CC4(C)C3C(O)CC12C HYTFUKZLSYXRDX-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- CWVRJTMFETXNAD-BMNNCGMMSA-N (1s,3r,4s,5r)-3-[(e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,4,5-trihydroxycyclohexane-1-carboxylic acid Chemical compound O[C@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-BMNNCGMMSA-N 0.000 description 1
- LTTQKYMNTNISSZ-MWTRTKDXSA-N (2S)-(-)-kurarinone Chemical compound C1([C@H]2OC=3C(C[C@@H](CC=C(C)C)C(C)=C)=C(O)C=C(C=3C(=O)C2)OC)=CC=C(O)C=C1O LTTQKYMNTNISSZ-MWTRTKDXSA-N 0.000 description 1
- YLRXAIKMLINXQY-ZDUSSCGKSA-O (S)-magnoflorine Chemical compound C1=C(OC)C(O)=C2C3=C(O)C(OC)=CC=C3C[C@@H]3[N+](C)(C)CCC1=C23 YLRXAIKMLINXQY-ZDUSSCGKSA-O 0.000 description 1
- NAOLWIGVYRIGTP-UHFFFAOYSA-N 1,3,5-trihydroxyanthracene-9,10-dione Chemical compound C1=CC(O)=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1 NAOLWIGVYRIGTP-UHFFFAOYSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010048461 Genital infection Diseases 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 241000175212 Herpesvirales Species 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 235000005206 Hibiscus Nutrition 0.000 description 1
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 description 1
- 244000048199 Hibiscus mutabilis Species 0.000 description 1
- 235000003973 Hibiscus mutabilis Nutrition 0.000 description 1
- 244000284380 Hibiscus rosa sinensis Species 0.000 description 1
- 235000013719 Houttuynia cordata Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010023138 Jaundice neonatal Diseases 0.000 description 1
- NYGZYUAVZPIKBZ-BDJLRTHQSA-N Kushenin Natural products O(C)c1c(O)cc2O[C@H]3[C@@H](c2c1)COc1c3ccc(O)c1 NYGZYUAVZPIKBZ-BDJLRTHQSA-N 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 206010024238 Leptospirosis Diseases 0.000 description 1
- NYGZYUAVZPIKBZ-UHFFFAOYSA-N Lespedezol D1 Natural products C1OC2=CC(O)=CC=C2C2C1C(C=C(C(=C1)O)OC)=C1O2 NYGZYUAVZPIKBZ-UHFFFAOYSA-N 0.000 description 1
- KYEAXNAYHSCLMT-CVVGWEDFSA-N Magnoflorine Natural products C[C@H]1OC=C2[C@@H]3[C@@H]1CN4CCc5c([nH]c6ccccc56)[C@@H]4[C@@H]3OC2=O KYEAXNAYHSCLMT-CVVGWEDFSA-N 0.000 description 1
- 241000244939 Menispermum dauricum Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 201000006346 Neonatal Jaundice Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- PTPHDVKWAYIFRX-UHFFFAOYSA-N Palmatine Natural products C1C2=C(OC)C(OC)=CC=C2C=C2N1CCC1=C2C=C(OC)C(OC)=C1 PTPHDVKWAYIFRX-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- PXRCIOIWVGAZEP-UHFFFAOYSA-N Primaeres Camphenhydrat Natural products C1CC2C(O)(C)C(C)(C)C1C2 PXRCIOIWVGAZEP-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- 244000296102 Selinum monnieri Species 0.000 description 1
- 235000019084 Selinum monnieri Nutrition 0.000 description 1
- 239000000877 Sex Attractant Substances 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- AAGFPTSOPGCENQ-UHFFFAOYSA-N Sophocarpin I Natural products C1CCC2CN3C(=O)C=CCC3C3C2N1CCC3 AAGFPTSOPGCENQ-UHFFFAOYSA-N 0.000 description 1
- IGXQFUGORDJEST-UHFFFAOYSA-N Sophocarpine Natural products O=C1C=CCC2C3CCCC4CCCC(CN12)C34 IGXQFUGORDJEST-UHFFFAOYSA-N 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 235000006754 Taraxacum officinale Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 1
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 description 1
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- 229930006739 camphene Natural products 0.000 description 1
- ZYPYEBYNXWUCEA-UHFFFAOYSA-N camphenilone Natural products C1CC2C(=O)C(C)(C)C1C2 ZYPYEBYNXWUCEA-UHFFFAOYSA-N 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 238000003763 carbonization Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000037902 enteropathy Diseases 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000002682 general surgery Methods 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 150000002496 iodine Chemical class 0.000 description 1
- KRZBCHWVBQOTNZ-DLDRDHNVSA-N isochlorogenic acid Natural products O[C@@H]1[C@H](C[C@@](O)(C[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)C(=O)O)OC(=O)C=Cc3ccc(O)c(O)c3 KRZBCHWVBQOTNZ-DLDRDHNVSA-N 0.000 description 1
- XQVFLLMCNGKXSM-UHFFFAOYSA-N kurarinone Natural products COc1cc(O)c(C(CC=C(C)C)C(=C)C)c2OC(CC(=O)c12)c3ccc(O)cc3O XQVFLLMCNGKXSM-UHFFFAOYSA-N 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- NYGZYUAVZPIKBZ-ZBEGNZNMSA-N lespedezol D1 Chemical compound C1OC2=CC(O)=CC=C2[C@H]2[C@@H]1C(C=C(C(=C1)O)OC)=C1O2 NYGZYUAVZPIKBZ-ZBEGNZNMSA-N 0.000 description 1
- 201000005630 leukorrhea Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 201000002266 mite infestation Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- KDADHLPROOOPIC-UHFFFAOYSA-N neokurarinol Natural products COc1cc(O)ccc1C1CC(=O)c2c(OC)cc(O)c(CC(CCC(C)(C)O)C(C)=C)c2O1 KDADHLPROOOPIC-UHFFFAOYSA-N 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- QUCQEUCGKKTEBI-UHFFFAOYSA-N palmatine Chemical compound COC1=CC=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)[N+]3=CC2=C1OC QUCQEUCGKKTEBI-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- GRWFGVWFFZKLTI-UHFFFAOYSA-N rac-alpha-Pinene Natural products CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 210000005122 simple epithelium Anatomy 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- AAGFPTSOPGCENQ-JLNYLFASSA-N sophocarpine Chemical compound C1CC[C@H]2CN3C(=O)C=CC[C@@H]3[C@@H]3[C@H]2N1CCC3 AAGFPTSOPGCENQ-JLNYLFASSA-N 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及消毒剂,提供了一种中西药结合的复方类消毒剂及其制备方法和应用。该消毒剂通过提取中药金银花,黄连,黄芩,黄柏,鱼腥草,苦参,地附子,蛇床子,蒲公英的有效成分为主要物质,配以西药氯己定为辅,将中西药按比例组合而制成,具有无臭、无味、无色,无毒副作用,无过敏反应,低耐药性等特点,性能稳定,对人体皮肤无刺激性,抗菌谱广,能够快速高效杀菌消毒,能够有效应用于各种区域位置的杀菌消毒。
Description
技术领域
本发明涉及消毒剂领域,更具体地说,涉及一种中西药结合的高效无毒副作用且广谱抗菌的复方消毒剂及其制备方法和应用。
背景技术
传统使用的消毒剂大多数均含有氯、醇类、醛类、碘类、过氧化物、有机酚化合物等成分,其对环境、器械、人体皮肤黏膜都有不同程度的影响。
目前,国内外主要的消毒剂主要有以下三类:一是以碘为主要成分的消毒剂,市场上此类产品主要有聚维酮碘,碘伏,碘酊等,带有颜色、起效速度慢且对皮肤具有刺激性等缺点;二是氯己定消毒液,被国际医学界广泛用于外科手术消毒,但是单纯的氯己定消毒效果不是很理想,对革兰氏阳性和阴性菌的灭杀消毒能力不足,难以达到完全杀灭细菌的效果;三是氯己定碘消毒液,由于氯己定碘难溶入水,所以大多都采用乙醇做溶剂,然后再加入大量助溶的表面活性剂,因而在使用时,会有很多泡沫和明显的滑腻感,且稳定性通常较差,应用领域受限,为人们不喜。除此之外,常见的消毒酒精虽然作用快,但容易产生耐药性。
中草药是中国医学宝库的重要组成部分,中国人民对中草药的探索经历了几千年的历史,其广泛的用于药品、渔业、保健食品、烟草、化妆品等行业。中草药植物中所含有的植物源抗菌物质广泛存在于自然界,利用的抗菌化合物大多是植物的次生代谢产物,包含生物碱类、类黄酮类、蛋白质类、有机酸类和酚类等化合物,是创制绿色杀菌剂的先导源。
因此,为克服上述传统消毒剂的缺点,需要一种无臭、无味、无色,无毒副作用,无过敏反应,低耐药性,性能稳定,对人体皮肤无刺激性,抗菌谱广,能够高效杀菌消毒,能够有效应用于各种区域位置的杀菌消毒。
发明内容
本发明的目的之一在于提供一种无臭、无味、无色,无毒副作用,无过敏反应,低耐药性,性能稳定,对人体皮肤无刺激性,抗菌谱广,能够快速高效杀菌消毒,能够有效应用于各种区域位置的杀菌消毒。
本发明是这样实现的,一种复方消毒剂,由中药提取物与西药制成的复方药液与基质混合制成,所述中药提取物包括金银花、黄连、黄芩、黄柏、鱼腥草、苦参、地附子、蛇床子和蒲公英的提取物,所述西药为氯己定或其药物上可接受的盐;所述复方药液中,中药提取物与氯己定或其药物上可接受的盐的混合重量比为1:3:2:1:5:2:4:1:2:0.01。
其中,所述氯己定或其药物上可接受的盐为醋酸氯己定、盐酸氯己定、葡萄糖酸氯己定中的至少一种。
进一步的,所述复方消毒剂中还包括稳定剂。
更进一步的,所述稳定剂选自聚乙二醇、聚乙烯吡咯烷酮、聚乙烯醇或聚氧乙烯中的一种或几种。
其中,所述复方消毒剂的剂型可以为液剂,其基质为纯化水。
其中,所述复方消毒剂的剂型也可以为霜剂,其基质为甘油或液体石蜡。
进一步的,所述复方消毒剂的pH值为7~8。
本发明的另一个目的在于提供上述复方消毒剂的制备方法,所述制备方法包括以下步骤:
A.选取中药金银花、黄连、黄芩、黄柏、鱼腥草、苦参、地附子、蛇床子和蒲公英,按重量比例将其碾碎、混合,放入反应锅,加纯化水煎煮至药性逼出,过滤掉药渣,然后离心去除药液中杂质,得到中药提取液;
B.将中药提取液放入适宜容器中,加热浓缩至稠糊状,倒入瓷盘中,放置于烘箱中进行烘焙结晶,得到中药提取物结晶体;
C.将中药提取物结晶体放入粉碎机中粉碎成800-1200目的细粉,得到中药提取物粉末;
D.将中药提取物粉末与沸水混合搅匀,并按重量比例加入西药,混合均匀,得到复方药液;
E.将复方药液与基质按比例混合,静置冷却分装,得到复方消毒剂。
其中,步骤B中的烘焙温度为50℃~70℃。
本发明还提供了上述复方消毒剂在消毒杀菌及疾病防疫中的应用。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合具体实施例,对本发明进行进一步详细说明。
在给出本发明的具体实施例之前,先对本发明中复方消毒剂的原材料及消毒原理进行介绍。
金银花,拉丁文,LoniceraJ aponica Thund,金银花的挥发油含有301多种有效成分,其中花营中含有木犀草素Iuteolin,肌醇inositoI和皂甙,分离出绿原酸chiorogenicacid,和异绿原酸isochiorogenic acid,它们是金银花抗菌作用的主要成分,根据张家(新中医)1973,6(3):155,李喜贤(中华医学杂志)1955,41(10):952,刘国华(中华新医学报)1950,1(2):95等大量报道表明,金银花对多种致病菌如金黄色葡萄球菌,大肠杆菌,绿服杆菌等众多的致病菌都有一定的抑制作用,另据湖南黔阳地区防疫站钩体病研究小组在流行病防治研究1975,(2):114报道金银花水煎剂(1:20)在人胚肾代原单层上皮细胞组织培养上,对流感病毒,孤儿病毒,疱疹病毒均有抑制作用。
黄连,拉丁文,CoptischinesisFranch。黄连主要含有黄连素7%---9%,黄连碱coptisine,甲基黄连碱worenine,药根碱jatrorrhizine,黄柏内脂bakulactone,黄连的抗病源微生物的功能,国内外研究报道甚多对葡萄球菌,链球菌,肺炎球菌,霍乱孤菌,炭瘟杆菌,病疾杆菌均有较强的抗菌作用,对金黄色葡萄球菌的抗菌功能优于青霉素。
黄芩别名山茶根、土金茶根。为唇形科植物黄芩(Scutellaria baicalensisGeorgi),以根入药。有清热燥湿,凉血安胎,解毒功效。主治温热病、上呼吸道感染、肺热咳嗽、湿热黄胆、肺炎、痢疾、咳血、目赤、胎动不安、高血压、痈肿疖疮等症。黄芩的临床应用抗菌比黄连还好,而且不产生抗药性。
黄柏含小檗碱、药根碱、木兰花碱、黄柏碱、N-甲基大麦芽碱、掌叶防己碱、蝙蝠葛碱等生物碱;另含黄柏酮、黄柏内酯、白鲜交酯、黄柏酮酸、青萤光酸、7-脱氢豆甾醇、β-谷甾醇、菜油甾醇。根皮含小檗碱、药根碱、黄柏碱、N-甲基大麦芽碱。木材也含小檗碱。黄柏的功效在于清热燥湿,泻火除蒸,解毒疗疮。用于湿热泻痢,黄疸,带下,热淋,脚气,痿{辟},骨蒸劳热,盗汗,遗精,疮疡肿毒,湿疹瘙痒。
鱼腥草,拉丁文,Houttuyniacordata,鱼腥草含有挥发油0.0049%,鱼腥草素decanoyIacetaldehyde,α-蒎烯(α-Pinene)、莰烯(Camphene)、月桂烯(Myrcene)和d-柠檬烯(d-Limonene)、甲基正壬基酮(Methyl-n-nonyl-ketone)、癸醛(Capric aldehyde)、癸酸(Capric acid)等有效成分。根据高学敏主编中药学(2003,1,497)和中国医学科学院药物研究所抗菌工作组,药学通报1960.8(2).59报道鱼腥草贤汁对金黄色葡萄球菌有抑制作用,多种体外抑菌实验方法均证明鱼腥草煎剂对金黄色葡萄球菌,白色葡萄球菌,流感杆菌,白色念球菌,大肠杆菌,肺炎双球菌,黄癣菌等均有明显的抑制作用。
苦参,拉丁文RadixSophoraeFiauescntis,主要含有苦参碱(matrine),氧化苦参碱(oxymatrine),N-氧化槐根碱(N-oxysophocaripine),槐定碱(sophoridine),苦参素(Kurarinone)。主要功效为清热燥湿,杀虫,利尿。用于热痢,便血,黄疸尿闭,赤白带下,阴肿阴痒,湿疹,湿疮,皮肤瘙痒,疥癣麻风;外治滴虫性阴道炎。根据临床验证,对淋球菌,金黄色葡萄球菌,大肠杆菌,及多种皮肤真菌均有较强的抑制作用。
蛇床子,拉丁文,FructusCnidii,主要含有蛇床素Cnidain,左旋蒎烯I-pinene,果实挥发油1.3%,功效为温肾壮阳,燥湿,祛风,杀虫。用于阳痿、宫冷、寒湿带下、湿痹腰痛;外治外阴湿疹、妇人阴痒、滴虫性阴道炎。
蒲公英,全草含蒲公英甾醇(Taraxasterol)、胆碱(Choline)、菊糖(Inulin)和果胶(Pectin)等。同属植物药用蒲公英(Taraxacum officinale)的根中含蒲公英醇(Taraxol)、蒲公英赛醇(Taraxerol)、-蒲公英甾醇、蒲公英甾醇、β-香树脂醇(βAmyrin)、豆甾醇(Stig-masterol)、β-谷甾醇(β-Sitosterol)等。蒲公英根性味甘,微苦,寒。具有清热解毒,消肿散结的作用。主要用于上呼吸道感染,眼结膜炎,流行性腮腺炎,乳痈肿痛,胃炎,痢疾,肝炎等疾病。
西药氯己定(俗称洗必泰),是一种二胍基化合物,为消毒皮肤、浸泡器械常用的消毒剂,也可内服治疗消化道感染,对肌体无毒性,对革兰氏阳性及阴性菌均有杀灭作用。在本发明中,氯己定或其药物上可接受的盐,优选醋酸氯己定、盐酸氯己定、葡萄糖酸氯己定中的至少一种,更优选为醋酸氯己定和葡萄糖酸氯己定。其中,选用醋酸氯己定作为原料,其优势在于便宜,使用成本较低,但常温下溶解度偏低,对人体黏膜刺激性稍大。而选用葡萄糖酸氯己定,虽价格成本高,但其优势在于常温下溶解度高且刺激性弱。
本发明提供了一种复方消毒剂,由中药提取物与西药制成的复方药液与基质混合制成,其中中药提取物包括金银花、黄连、黄芩、黄柏、鱼腥草、苦参、地附子、蛇床子和蒲公英的提取物,所述西药为氯己定或其药物上可接受的盐;所述复方药液中,中药提取物与氯己定或其药物上可接受的盐的混合重量比为1:3:2:1:5:2:4:1:2:0.01。
在本发明的一个具体实施例中,所述复方药液中,中药提取物与西药的组分及含量分别为:金银花500g,黄连1500g,黄岑1000g,黄柏500g,鱼腥草2500g,苦参1000g,地附子2000g,蛇床子500g,蒲公英1000g,西药为醋酸氯己定5g。本实施例的复方药液,使用成本低;为提高西药的溶解度,中西药更好的混匀,可以在混匀过程中,升温搅匀。
在本发明的另一个具体实施例中,所述复方药液中,中药提取物与西药的组分及含量分别为:金银花500g,黄连1500g,黄岑1000g,黄柏500g,鱼腥草2500g,苦参1000g,地附子2000g,蛇床子500g,蒲公英1000g,西药为葡萄糖酸氯己定5g。本实施例的复方药液,常温下中西药溶解混匀较为容易。
为使本发明提供的复方消毒剂有效成分更为稳定,在制备过程中,本发明还可以在复方药液中加入稳定剂,稳定剂可以选择聚乙二醇、聚乙烯吡咯烷酮、聚乙烯醇或聚氧乙烯中的一种或几种。
同时,为拓宽本发明复方消毒剂的应用方式及应用位置,本发明的复方消毒剂利用不同的基质与复方药液混合,制备成不同的剂型。在本发明的一个具体实施例中,利用纯化水作为基质与复方药液混合,基质与复方药液的重量比为2~2.5:1,制备成剂型为液剂的复方消毒剂,其优势在于使用便利,直接喷洒即可,消毒杀菌更为深入彻底。而在本发明的另一个具体实施例中,利用甘油作为基质与复方药液混合,基质与复方药液的重量比为1~1.5:1,制备成剂型为霜剂的复方消毒剂,其优势在于涂抹于目的位置,杀菌消毒持久,可以长效抑制病毒细菌。
为降低本发明复方消毒剂在使用过程中对于人体黏膜的过敏反应及刺激性,本发明复方消毒剂的pH值为7~8,优选pH值为7.2~7.5。上述pH值可以使得所述复方消毒剂的使用酸碱值与人体黏膜环境的酸碱值接近,降低人体黏膜对复方消毒剂的过敏反应,减弱刺激感。
本发明还提供了上述复方消毒剂的制备方法,所述制备方法包括以下步骤:
A.选取中药金银花、黄连、黄芩、黄柏、鱼腥草、苦参、地附子、蛇床子和蒲公英,按重量比例将其碾碎、混合,放入反应锅,加纯化水煎煮至药性逼出,过滤掉药渣,然后离心去除药液中杂质,得到中药提取液;
B.将中药提取液放入适宜容器中,加热浓缩至稠糊状,倒入瓷盘中,放置于烘箱中进行烘焙结晶,得到中药提取物结晶体;
C.将中药提取物结晶体放入粉碎机中粉碎成800-1200目的细粉,得到中药提取物粉末;
D.将中药提取物粉末与沸水混合搅匀,并按重量比例加入西药,混合均匀,得到复方药液;
E.将复方药液与基质按比例混合,静置冷却分装,得到复方消毒剂。
其中,步骤A中,为保证最后制得的复方消毒剂无臭无色无味,离心速度可选择10000~13000rpm,离心时间为20~40min,以便药液中的杂质完全沉淀下来,得到透明清亮的中药提取液。
同时,在步骤B中,为防止得到的中药提取物结晶体中带有其他杂质,影响复方消毒剂最后的成色及有效成分,烘焙结晶的温度不能过高,可以选择50℃~70℃,优选为55℃~65℃,既保证中药提取液能被快速烘干浓缩结晶,又不会出现浓缩结晶中碳化的现象。
如之前所述,步骤D中的西药可以为氯己定或其药物上可接受的盐,常见的包括但不限于醋酸氯己定、盐酸氯己定、柠檬酸氯己定和葡萄糖酸氯己定,优选为醋酸氯己定、盐酸氯己定和葡萄糖酸氯己定,更优选为醋酸氯己定和葡萄糖酸氯己定。药物上可接受的氯己定盐可以增加其有效成分的溶解度,更好的与中药提取物之间相互混匀,提高复方消毒剂的功效。
步骤E中所述的基质,根据复方消毒剂制备的剂型,可以选择纯化水、甘油或液体石蜡,在本发明的一个具体实施例中,为制备得到液剂的复方消毒剂,利用纯化水作为基质与复方药液混合;在本发明的另一个具体实施例中,利用甘油作为基质与复方药液混合,制备得到霜剂的复方消毒剂。上述实施例中,复方药液与基质之间的重量比例为1:1~1.5。
本发明还提供了上述复方消毒剂在消毒杀菌及疾病防疫中的应用。其应用包括但不限于下述具体应用:
所述复方消毒剂可以用于环境的清洁,适用于个人,家庭,公共场所,人群密集场所的喷洒消毒。
所述复方消毒剂可以适用于医疗环境场所的清洁消毒;如病房、手术室,防止院内交叉感染等。
所述复方消毒剂可以适用于餐饮业,宾馆住宿业、旅途、航空、船舶、运输、娱乐场所等行业的保洁,消毒、防病。
所述复方消毒剂可以适用于养殖业,种殖业,对动、植物的病虫害都有消杀抑制作用。
所述复方消毒剂可以用于多种感染病的防疫,治疗作用,如:泌尿急慢性尿道炎,生殖器感染病如:阴道炎,子宫康烂,淋病,梅菌,光锐湿莎等;可以用于多种内外粘膜病的防治,如:月工肠病、鼻炎、口腔溃荡,牙根炎、咽喉炎、耳道炎等。用于各种细菌真菌传染性皮肤病,如各种癖、疮荡、斑莎,皮肤溃烂,烧伤,烫伤等的治疗。
为证明本发明复方消毒剂的特性,本发明提供针对所述复方消毒剂的药效学试验及结果。
1、消毒杀菌药效试验
将制备好的液态复方消毒剂,利用试管法进行药效学试验:用肉汤将复方消毒剂稀释至100μg/mL,然后递减稀释10管,分别加入供试代表菌株液0.5mL,37℃培育24h,稀释时普通细菌用肉汤培养基;氧厌菌用硫乙醇酸盐培养基,供试菌株:用卫生部临床质控中心菌株:大肠杆菌(ATCC25922),金葡菌(ATCC6538),绿服杆菌(ATCC27853),破伤风梭菌(罗L),产气芙膜梭菌(PB6K)为兰州生物制品研究所惠赠,供试菌株液为稀释30倍之后的24h培养液,结果见表l。
表1.复方消毒剂药效测定(试管法)
注:“―”代表无菌生长;“+”代表有菌生长。
从表1的结果中可以看出,本发明的复方消毒剂对于革兰氏阳性及阴性菌均有很强的杀菌作用。其中金葡菌的杀灭能力可达到在0.39mg/mL浓度时仍为阴性结果;而绿脓杆菌由于其膜结构的特性,存在渗障壁抑制了药物渗入的缘故,对消毒剂的抵抗力比一般革兰氏阴性菌强大,杀灭效果稍差。
2、起效时间试验
试验方法:以供试菌株24h培养后得到的肉汤培养液0.1mL加入1.9mL本发明的液态复方消毒剂中,然后每隔2.5min取出0.005mL(2mm直径铂金环一满环),接种于5mL肉汤管内,37℃培育24h后观察有无菌生长。作为对比,以同样的方法对现在市面上常用的75%酒精消毒液、1%新洁尔灭、洁尔阴和84消毒液进行试验,试验结果见表2。
表2.起效时间试验结果
由表2结果可以看出,本发明的复方消毒剂2.5min之后即可对供试菌株完全起消毒杀菌作用,起效时间远快于目前市面上常用的消毒杀菌药剂,说明本发明的复方消毒剂可以快速进行消毒杀菌。
3、杀菌效果试验
为进一步证明本发明的复方消毒剂杀菌效果,特别是对人体皮肤以及特定的医疗器械的消毒杀菌作用,本发明做了进一步试验。
其中的一个试验,用本发明的复方消毒剂、75%酒精消毒液和1%新洁尔灭对手术室医生进行泡手消毒试验,各做100人次。受试者浸泡手15分钟,擦干,用生理盐水棉签拭手指后投入肉汤中,置37℃培养24h,观察有无菌生长,结果显示本发明的复方消毒剂结果均优于后两种消毒液。
在另一个试验中,以本发明的复方消毒剂浸泡棉球进行消毒,以供妇科、普外科、门诊注射室进行观察使用,作皮肤消毒后进行穿刺,共做了10000人次。结果显示,以本发明的复方消毒剂浸泡消毒过的棉球无一例感染。
4、耐药性试验
将表l第9管生长菌作为供试菌株液,将其移种于不同的复方消毒剂肉汤培养内进行药敏试验,连续诱导10天未见滴度变化。此外,根据发明人多年来在临床应用中的研究结果表明,尚未发现对复方消毒剂的耐药性菌株。其原因可能是中药与氯己定制配在一起,对细菌的作用位占较多,例如可使蛋白质或酶变性和沉淀,与DNA和PNA作用,破坏菌细胞组织结构增强通透性,干扰分解代谢,阻碍能量产生,两者合用增强了药物表面活性作用,并影响菌细胞反相转氨酶活性的作用,故可协同增效。
5、稳定性试验
将配制好的复方消毒剂放置于4℃冰箱或室温一年,然后再用大肠杆菌及金葡菌等供试菌株重复“消毒杀菌药效试验”,经测定结果验证其亦无影响。
6、过敏性、刺激性及毒性试验
利用饲养的家兔三只,在其右眼滴入本发明的复方消毒剂一滴,左眼滴入0.85%生理盐水一滴,分别于12h及24h进行观察,无充血及红肿现象;此外,利用本发明浓度为7.5μg/mL的复方消毒剂,加入1640细胞培养液中进行淋巴细胞转化试验,结果显示对细胞转化并无影响,因此证明本发明的复方消毒剂的细胞毒性试验结果良好。
综合上述实施例及试验数据和结果,说明本发明所提供的复方消毒剂,是一种无臭、无味、无色,无毒副作用,无过敏反应,低耐药性,性能稳定,对人体皮肤无刺激性,抗菌谱广,能够快速高效杀菌消毒,能够有效应用于各种区域位置的消毒剂。
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等,均应包含在本发明的保护范围之内。
Claims (7)
1.一种复方消毒剂,由中药提取物与西药制成的复方药液与基质及稳定剂混合制成,其特征在于,所述中药提取物由金银花、黄连、黄芩、黄柏、鱼腥草、苦参、地附子、蛇床子和蒲公英的提取物组成,所述西药为氯己定或其药物上可接受的盐;所述复方药液中,所述中药提取物中的金银花、黄连、黄芩、黄柏、鱼腥草、苦参、地附子、蛇床子和蒲公英的提取物与氯己定或其药物上可接受的盐的混合重量比为1:3:2:1:5:2:4:1:2:0.01;
所述复方消毒剂的剂型为液剂时,其基质为纯化水,所述纯化水与复方药液的重量比为2~2.5:1;
所述复方消毒剂的剂型为霜剂时,其基质为甘油或液体石蜡,所述甘油或液体石蜡与复方药液的重量比为1~1.5:1。
2.根据权利要求1所述的复方消毒剂,其特征在于,所述氯己定或其药物上可接受的盐为醋酸氯己定、盐酸氯己定、葡萄糖酸氯己定中的至少一种。
3.根据权利要求1所述的复方消毒剂,其特征在于,所述稳定剂为选自聚乙二醇、聚乙烯吡咯烷酮、聚乙烯醇或聚氧乙烯中的一种或几种。
4.根据权利要求1至3任一项所述的复方消毒剂,其特征在于,所述复方消毒剂的pH值为7~8。
5.根据权利要求1至4任一项所述复方消毒剂的制备方法,其特征在于,所述复方消毒剂的制备方法包括以下步骤:
A.选取中药金银花、黄连、黄芩、黄柏、鱼腥草、苦参、地附子、蛇床子和蒲公英,按重量比例将其碾碎、混合,放入反应锅,加纯化水煎煮至药性逼出,过滤掉药渣,然后离心去除药液中杂质,得到中药提取液;
B.将中药提取液放入适宜容器中,加热浓缩至稠糊状,倒入瓷盘中,放置于烘箱中进行烘焙结晶,得到中药提取物结晶体;
C.将中药提取物结晶体放入粉碎机中粉碎成800-1200目的细粉,得到中药提取物粉末;
D.将中药提取物粉末与沸水混合搅匀,并按重量比例加入西药,混合均匀,得到复方药液;
E.将复方药液与基质按比例混合,静置冷却分装,得到复方消毒剂。
6.根据权利要求5所述复方消毒剂的制备方法,其特征在于,步骤B中的烘焙温度为50℃~70℃。
7.根据权利要求1至4任一项所述复方消毒剂在消毒杀菌及疾病防疫中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510247163.4A CN104920499B (zh) | 2015-05-15 | 2015-05-15 | 一种复方消毒剂及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510247163.4A CN104920499B (zh) | 2015-05-15 | 2015-05-15 | 一种复方消毒剂及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104920499A CN104920499A (zh) | 2015-09-23 |
| CN104920499B true CN104920499B (zh) | 2018-10-23 |
Family
ID=54108213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510247163.4A Expired - Fee Related CN104920499B (zh) | 2015-05-15 | 2015-05-15 | 一种复方消毒剂及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104920499B (zh) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105213359B (zh) * | 2015-09-25 | 2018-05-18 | 湖北穆兰同大科技有限公司 | 女性私密护理液及其制备方法 |
| CN105248461A (zh) * | 2015-11-18 | 2016-01-20 | 李爱冰 | 一种家用消毒液及其制备方法 |
| CN105342920B (zh) * | 2015-11-25 | 2018-06-08 | 山西振东家庭健康护理用品有限公司 | 一种中药抑菌养护沐浴液及其制备方法 |
| CN105770228A (zh) * | 2016-04-29 | 2016-07-20 | 青岛市中心医院 | 一种用于手术前消毒的洗手液 |
| CN106035428A (zh) * | 2016-05-26 | 2016-10-26 | 安徽禹王养殖有限公司 | 一种用于生猪养殖场中草药消毒剂及其制备方法 |
| CN106359470A (zh) * | 2016-08-30 | 2017-02-01 | 四川创美克科技有限公司 | 一种复方中药消毒剂及其制备方法和用途 |
| CN107970307A (zh) * | 2016-10-21 | 2018-05-01 | 鼎正动物药业(天津)有限公司 | 一种防治水产养殖细菌性疾病的中药消毒剂及其制备方法 |
| CN107897222A (zh) * | 2017-12-21 | 2018-04-13 | 苏州希尔盖森新材料有限公司 | 一种衣物专用消毒粉 |
| CN108576081A (zh) * | 2018-01-24 | 2018-09-28 | 合肥华盖生物科技有限公司 | 一种医疗器材用环保型中药消毒剂及其制备方法 |
| CN108210615A (zh) * | 2018-03-28 | 2018-06-29 | 潍坊红阳药业有限公司 | 一种抑菌喷剂及其制备方法 |
| CN109221292A (zh) * | 2018-11-13 | 2019-01-18 | 铜仁学院 | 一种药物消毒剂及其制备方法 |
| CN110354034A (zh) * | 2019-07-23 | 2019-10-22 | 陕西中医药大学附属医院 | 一种环保型中药复方手消毒剂及其制备方法 |
| CN112136838A (zh) * | 2020-08-27 | 2020-12-29 | 东莞市泰赛特汽车用品科技有限公司 | 一种温和无毒的杀菌消毒剂、制备方法及其应用 |
| CN115844967B (zh) * | 2022-09-06 | 2024-08-02 | 贵州碘雅医疗器械有限公司 | 一种复合碘消毒液及其制备方法和应用 |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1165028A (zh) * | 1997-05-26 | 1997-11-19 | 褚成炎 | 强力消毒液 |
| CN1397168A (zh) * | 2001-07-13 | 2003-02-19 | 周茜 | 复合消毒剂 |
| CN1568712A (zh) * | 2003-07-18 | 2005-01-26 | 陈炳炎 | 一种中药复方消毒灭菌剂的配方 |
| CN102579701A (zh) * | 2012-02-24 | 2012-07-18 | 洪长征 | 复方蒲公英煎剂 |
| CN102755640A (zh) * | 2011-04-27 | 2012-10-31 | 林治 | 植物中草药精华素复配消毒液 |
| CN103444801A (zh) * | 2013-08-19 | 2013-12-18 | 河北省科学技术情报研究院 | 一种图书馆消毒用中药杀菌清新制剂 |
| CN103493853A (zh) * | 2013-09-25 | 2014-01-08 | 合肥智上农业开发有限公司 | 一种消毒液 |
| CN103891784A (zh) * | 2013-09-11 | 2014-07-02 | 安徽亿人安有限公司 | 一种杀菌消毒的抑菌剂与皮肤黏膜消毒液及其制备方法 |
-
2015
- 2015-05-15 CN CN201510247163.4A patent/CN104920499B/zh not_active Expired - Fee Related
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1165028A (zh) * | 1997-05-26 | 1997-11-19 | 褚成炎 | 强力消毒液 |
| CN1397168A (zh) * | 2001-07-13 | 2003-02-19 | 周茜 | 复合消毒剂 |
| CN1568712A (zh) * | 2003-07-18 | 2005-01-26 | 陈炳炎 | 一种中药复方消毒灭菌剂的配方 |
| CN102755640A (zh) * | 2011-04-27 | 2012-10-31 | 林治 | 植物中草药精华素复配消毒液 |
| CN102579701A (zh) * | 2012-02-24 | 2012-07-18 | 洪长征 | 复方蒲公英煎剂 |
| CN103444801A (zh) * | 2013-08-19 | 2013-12-18 | 河北省科学技术情报研究院 | 一种图书馆消毒用中药杀菌清新制剂 |
| CN103891784A (zh) * | 2013-09-11 | 2014-07-02 | 安徽亿人安有限公司 | 一种杀菌消毒的抑菌剂与皮肤黏膜消毒液及其制备方法 |
| CN103493853A (zh) * | 2013-09-25 | 2014-01-08 | 合肥智上农业开发有限公司 | 一种消毒液 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104920499A (zh) | 2015-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104920499B (zh) | 一种复方消毒剂及其制备方法和应用 | |
| Céline et al. | Medicinal plants from the Yanesha (Peru): Evaluation of the leishmanicidal and antimalarial activity of selected extracts | |
| CN106538638B (zh) | 一种中药消毒剂及其制备方法 | |
| CN113244296B (zh) | 一种药物挥发油组合物及其制备方法和应用 | |
| CN106900781B (zh) | 一种植物中草药制备的抗菌抑菌液 | |
| CN103271102A (zh) | 奶牛场用中草药环保消毒剂 | |
| CN103451032B (zh) | 安全环保茶籽洗洁粉及其制备方法 | |
| CN103622865B (zh) | 一种包含植物提取精油的医疗用洗手液及其制备方法 | |
| CN103705649B (zh) | 一种检验科用杀菌消毒液及制备方法 | |
| CN104524021A (zh) | 一种检验科用消毒剂及制备方法 | |
| Khan et al. | Medicinal plants of Sewa river catchment area in the Northwest Himalaya and its implication for conservation | |
| CN104922248A (zh) | 一种抗菌、消炎中药复方凝胶剂及制备方法 | |
| CN103933275A (zh) | 一种抗菌消毒药剂及其制作方法 | |
| CN110314178A (zh) | 具有广谱杀菌活性的纯天然复方精油及其制备和用途 | |
| CN103463317B (zh) | 一种治疗鱼类白头白嘴病的药物组合物及其制备方法 | |
| Bhunia et al. | Antibacterial activity of Alpinia L.(Zingiberaceae) from Santal and Lodha tribal areas of Paschim Medinipur district in Eastern India | |
| CN104491121A (zh) | 一种用于治疗呼吸道疾病的抗菌精华液及其制备方法 | |
| Tijjani et al. | Studies on antibacterial activity of Adenium obesum (Apocynaceae) stembark. | |
| Paul et al. | A preliminary survey of ethno-medicinal plants used by the Chakma community of Rangamati and Khagrachari Hill District, Bangladesh | |
| US11173101B1 (en) | Silver ion bacteriostatic hand sanitizer and preparation method and application thereof | |
| ES2697049T3 (es) | Composiciones basadas en plantas y utilizaciones | |
| Tiwari et al. | Antimicrobial activity evaluation of the root of Carica papaya Linn | |
| CN107637589A (zh) | 猪精液稀释液及其生产方法 | |
| Omilani | Ethnobotanical survey of the medicinal plants used in the treatment of sexually transmitted diseases in Ibadan, Oyo State, Nigeria | |
| KR20100104625A (ko) | 고삼, 애엽, 작약 및 홍삼을 포함하는 여성 국부세정용 한방 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20181023 Termination date: 20190515 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |